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Abstract 
Background: Hepatitis C virus (HCV) is a major health concern where about 3 % of the world’s population is infected 
globally. In Ethiopia the prevalence ranges from 0.9 to 1.3 % in the general populations. Human immune deficiency 
virus (HIV) patients due to their weak immune response are heavily affected by the virus. There is no data on mag-
nitude and associated risk factors for HCV infection among voluntary counseling, testing center and anti retroviral 
treatment clinic Attendants in the study area. Therefore, the aim of this study was to determine the sero-prevalence 
and associated risk factors for HCV infection among voluntary counseling testing and anti retroviral treatment clinic 
attendants Adwa general hospital.
Methods: Cross sectional study was carried out among 302 participants (151 HIV-negative from VCT and 151 HIV-
positive from ART follow up) clinics of Adwa hospital from September to December, 2014. About 5 ml of venous 
blood samples were collected from study participants for anti HCV antibody tests. Univariate analyses were used to 
identify associated variables with anti HCV positivity. Variables having p < 0.05 were considered as statistically signifi-
cant association.
Results: Out of the total 302 participants, 52.6 % of them were females and 47.4 % males. The mean age of the 
participants was 34.1 year (SD ± 10.5). The overall sero-prevalence of HCV in this study was 4.3 %. The prevalence HCV 
(6.6 %) was higher among the ART clinic attendants than the VCT (2 %) clinic attendants. History of hospitalization 
(p = 0.001), tooth extraction (p = 0.018) and blood transfusion (p = 0.041) showed statistically significant association 
with anti-HCV antibody.
Conclusion: HCV sero-prevalence in this study was high. The prevalence was three fold higher among HIV positive 
patients than their counter parts. Thus, screening of HCV should be done among HIV patients for close monitoring 
and better management in HIV patients.
Keywords: HCV, Sero-prevalence, Risk factors, VCT clinic, ART clinic, Adwa hospital
© 2016 Atsbaha et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
BMC Research Notes
*Correspondence:  araya13e25@gmail.com; araya.gebreyesus@mu.edu.et 
1 Department of Medical Microbiology and Immunology, Institute 
of Biomedical Science, College of Health Sciences, Mekelle University, 
P.O.Box: 1871, Mekelle, Ethiopia
Full list of author information is available at the end of the article
Page 2 of 6Atsbaha et al. BMC Res Notes  (2016) 9:121 
Background
Infection with hepatitis C virus (HCV) is a major cause 
of chronic hepatitis, cirrhosis, and hepato cellular car-
cinoma around the world [1]. About 3  % of the world’s 
population have HCV with 170 million chronic carri-
ers at risk of developing liver cirrhosis, and annual new 
infection rate of four million [2]. The prevalence of HCV 
is higher in developing nation like the sub-Saharan Africa 
[3].
Above 80  % of the HCV exposed individuals become 
chronically carriers, and 30  % of them develop chronic 
liver disease [4]. High-risk groups who have exposure 
with blood or blood products, like intravenous drug use, 
patients with pediatric hematologic malignancies, long 
term haemo-dialysis, with organ transplantation, infants 
born to HCV positive mothers and un-protective sex are 
highly infected with HCV [5].
Due to the similar routes of transmissions and expo-
sure, HIV patients are highly infected with HCV; as a 
result there are about four to five million HIV/HCV co-
infection globally [4]. As HIV virus declines the immune 
response of the patients to HCV, this results in lower 
viral clearance of HCV infection, increased levels of HCV 
RNA in the blood, rapid progression to HCV-related end 
stage liver disease and increased risk of antiretroviral 
associated liver toxicity [6]. These HCV related complica-
tion in HIV patients highlights the importance of timely 
and appropriate diagnosis and treatment to prevent fur-
ther spread of HCV infections and improve their quality 
of life [7].
Hence, magnitude of HCV infections in patient popu-
lations in different areas and risk factors for the trans-
mission should be investigated to take measures for 
reduction of such transmission in the populations. In 
Ethiopia there are few studies done on prevalence of 
hepatitis infections [8–15] and HCV/HIV co-infection 
[16–19].
Although screening based on antibody detection 
could markedly reduce the risk of HCV infection [20], 
little emphasis is given for viral hepatitis co-infections 
in HIV patients in Ethiopia and recent ART guide-
lines don’t recommend routine screening tests for 
HCV [21], rather recommends only for alanine amino 
transferase (ALT) levels test to determine liver related 
complications among HIV patients. The magnitude of 
HCV among HIV positive and negative participants 
and its associated risk factors isn’t known in the study 
area. Therefore this study was aimed to fill the exist-
ing knowledge gap on HCV prevalence in the study 
area.
Methods
Study design, study period and sample size determination
Prospective cross-sectional study was conducted from 
September to December, 2014 at Adwa hospital which is 
located in Central Zone of Tigray regional state, north-
ern Ethiopia. Three hundred two study participants (151 
HIV-negative from VCT and 151 HIV-positive subjects in 
ART follow up) were enrolled in the study. Adwa town is 
located at longitude and latitude of 14°15′N and 38°54′E at 
an elevation of 1907 meters above sea level. It is 1006 km 
north of Addis Ababa (the capital city of Ethiopia) and 
223 km far from North–West of Mekelle, the capital city of 
Tigray national regional state. Adwa General hospital cov-
ers four catchment Woredas and serves for an estimated 
population of more than 970,644. Adwa general hospital is 
the main center for ART and VCT center in the zone.
Sample size determination
The sample size was calculated using a double propor-
tion formula by considering the seroprevalence of HCV 
in HIV positive (p1) and HIV negative study participants 
(p2) which is 9.2 and 1.58  %, respectively Hadush et  al. 




 average proportion, q¯ = 1− p¯r = Ratio of HIV 
positive to HIV negative individuals  =  n1/n2  =  1 for 
equal sample size.
P1 = Prevalence of HCV among HIV positive individuals.
P2  =  Prevalence of HCV among HIV negative 
individuals.
Zα/2  =  The z-score corresponding to the probability 
with which it is desirable to be able to conclude that an 
observed difference of size (p1 − p2) of variables between 
HIV positive and HIV negative individuals will not occur 
by chance = 1.96.
Zβ = the score corresponding to the degree of confidence 
with which it is desired to certain of detecting a differ-

























q¯ = 1− p¯ = 1− 0.0539 = 0.9461
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n1 = n2 = 0.79273
0.005806
= 137 from each group with a total 
of 274 participants. However, to increase the power of 
the study we added 10 % contingency, 137 × 10
100
=∼ 14 , 
and 14 +  137 =  151 in each group with a total of 302 
participants.
Inclusion and exclusion criteria
All HAART naive adult HIV positive study participants 
who visited ART clinic for their pre ART follow up and 
other laboratory investigation during the study period 
were included in the study. Individuals who visited VCT 
clinic and sero negative for HIV testing regardless of 
other risk factors during the study period were included 
in the study. Children, and individuals who refused and 
unable to give informed consent were excluded from the 
study.
Data collection procedure
Socio-demographic data and risk factors such as, drug 
injection, dental procedure, surgery, blood transfusion, 
hospitalization, history of tattooing, scarification, multi-
ple sexual partners, abortion, STI and visiting traditional 
healers were collected using standard questioner by clini-
cal nurses working in the hospital.
Blood sample collection and processing
Approximately 5 ml of venous blood was collected using 
vacationer tube and then serum was separated by cen-
trifugation at 3000 rpm for 10 min. Clear non-hemolysed 
serum specimens were tested for HCV by Anti-HCV 
Rapid Test kits (Zhejiang Orient Gene Biotech Co.LTD, 
China) according to the manufacturer’s instruction. The 
presence of antibodies to HIV for the VCT attendants 
was determined using the standard methods available to 
determine the test in the hospital.
Quality control and data analysis
The Quality of the study was maintained by strictly fol-
lowing standard operational procedures during labo-
ratory investigation. Internal quality control was done 
using known anti-HCV-antibody positive and anti-HCV-
antibody negative samples. The data was entered and 
analyzed using SPSS version 20.0 statistical software. Chi 
square test (χ2) was used to see the association with HCV 
and p value of less than 0.05 was considered as statisti-
cally significant.














Ethical clearance was obtained from the Ethical Review 
committee of the College of Health Science, Mekelle 
University (Ref. no: ERC 0459/2014). Official letter of 
permission was obtained from Tigray Regional Health 
Bureau and Adwa General Hospital. Written consent was 
obtained from all study participants. Confidentiality was 
kept and participants who were found to be positive for 
HCV were communicated by the health care workers for 
further management.
Results
Socio‑demographic and sero‑prevalence of HCV 
among participants
Among the total 302 study participants of VCT and 
ART clinics (response rate 100 %), 52.6 % of them were 
females and 47.4 % were males. The mean age of partici-
pants was 34.1 years (SD ± 10.5). One hundred and nine-
teen (39.4  %) of the participants were in the age range 
of 18–29  years. Fifty percent of the study participants 
were single, and 47.0 % of them have attained secondary 
school or above.
The overall seroprevalence of anti-HCV antibody in 
this current study was 13 (4.3). HCV prevalence was 
relatively higher in the age group of 40–49 years and in 
male, but not statistically significant (p  >  0.5). Similarly 
higher sero-prevalence was seen among divorced, farm-
ers and illiterate participants but not statistically signifi-
cant (Table 1). In this study, HCV infection was higher in 
HIV positive patients 10 (6.6 % than the negative 3 (2 %) 
patients (Table 2).
Associated risk factors and HCV sero‑prevalence
In this study, previous history of hospitalization 
(χ2  =  15.635, p  =  0.001), tooth extraction (χ2  =  5.569, 
p = 0.018) and blood transfusion (χ2 = 4.349, p = 0.041) 
have shown a statistically significant association with 
sero-prevalence of HCV. Dental procedure, surgery, mul-
tiple sexual partners, history of abortion, STI and visit-
ing traditional healers however; showed no statistically 
significant association with HCV infection (p  >  0.05) 
(Table 3).
Discussion
Sero-prevalence of HCV among HIV negative and HIV 
positive in this study was (4.3 %, with prevalence rate of 2 
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and 6.6 % in HIV negative and HIV positive participants 
respectively. The overall sero-prevalence of HCV in this 
study (4.3 %) was comparable with results from Burkina 
Faso 5.4 % [22], Malawi 4.5 % [23] and Ghana 3.6 % [24], 
however, it was higher than reports from Addis Ababa, 
0.9  % [17] and Debretabor, South Gondar 1.3  % [12]. 
Higher value of prevalence than our result was reported 
from other parts of Ethiopia, Mekelle, 6 % [18] and South 
Gondar 7.5 % [8].
HCV/HIV coinfection rate in this study, 6.6  % was 
comparable with the studies done in Gonder, 5.0 % [25], 
Mekelle, 8.6  % [18], Nigeria, 8.2  % [26] and Malawi, 
5.7 % [27]. Our result was however; higher than reports 
from other parts of Ethiopia like Debretabor Hospital, 
South Gondar, 1.3 % [12], Bahir Dar, 5.5 % [15], North-
west Ethiopia, 1.7 % [13], and Burkina Faso, 4.8 % [22], 
Malawi, 4.5  % [23], Zimbabwe, 0.8  % [28], Zambia, 
2.2 % [29], Rwanda 4.9 % [30], Ghana, 3.6 % [24], South-
Africa, 1 % [31], Gambia, 0.6 % [32], Zambia, 1.2 % [33], 
Senegal, 1.6 % [34], Uganda, 3.3 % [35] and Cote D’voir, 
1.2 % [36].
Higher HCV/HIV coinfection was documented from 
Hawassa, South Ethiopia, 9.2  % [19] and Addis Ababa, 
11.6  % [17], Cameroon, 8.6  % [37] and Kenya, 10.3  % 
[38].
These variations could be due to differences in geo-
graphic regions, types of risk exposure and methodology 
used [39, 40]. The higher HCV co-infection rate in HIV 
patients in this study and other places could be due to the 
shared modes of transmission of both viruses in the study 
Table 1 Seroprevalence of HCV by socio-demographic variables among VCT and ART clinic attendants in Adwa general 
hospital from September to December, 2014
Variables HCV‑antibody χ2 p value
Positive no (%) Negative no (%) Total no (%)
Age group
 18–29 4 (3.4) 115 (96.6) 119 (39.4) 0.975 0.807
 30–39 4 (4.3) 58 (93.5) 62 (20.5)
 40–49 4 (6.5) 26 (96.3) 27 (8.9)
 ≥50 1 (3.7) 90 (95.7) 119 (39.4)
Sex
 Male 7 (4.9) 136 (95.1) 143 (47.4) 0.038 0.845
 Female 6 (3.8) 153 (96.2) 159 (52.6)
Marital status
 Married 3 (2.9) 99 (97.1) 102 (33.8)
 Single 7 (4.6) 145 (95.4) 152 (50.3)
 Divorced 2 (6.9) 27 (93.1) 29 (9.6) 1.009 0.799
 Widowed 1 (5.0) 18 (94.7) 19 (6.3)
Educational status
 Illiterate 4 (7.4) 50 (92.6) 54 (17.9)
 Elementary school 5 (4.7) 101 (95.3) 106 (35.1) 2.069 0.355
 High school and above 4 (2.8) 138 (97.2) 142 (47.0)
Occupational category
 Unemployed 4 (4.2) 91 (95.8) 95 (31.5)
 Private employee 5 (4.7) 102 (95.3) 107 (35.4)
 Government 1 (2.6) 38 (97.4) 39 (12.9) 0.382 0.996
 Farmer 1 (5.0) 19 (95.0) 20 (6.6)
 House wife 1 (4.8) 20 (95.2) 21 (7.0)
 Sex worker 1 (5.0) 19 (95.0) 20 (6.6)
Table 2 Comparison of HIV/HCV coinfection between VCT 
and ART clinics at Adwa hospital (September to December, 
2014.)





Total no  
(%)
Positive 10 (6.6) 141 (93.4) 151 (50) 4.146 0.085
Negative 3 (2.0) 148 (98.0) 151 (50)
Total 13 (4.3) 289 (96.7) 302 (100)
Page 5 of 6Atsbaha et al. BMC Res Notes  (2016) 9:121 
patients [17, 41]. Hence investigation of HCV in HIV-
positive patients is crucial to prevent them from further 
infections and complications [42].
HCV prevalence among VCT clinic attendants in this 
current study (2  %) was comparable with results from 
Mekelle, Ethiopia, 1.65  % [18]; but lower than that of 
Addis Ababa (5 %) [16].
There was no statistically significant association 
between sero-prevalence rate of HCV and marital sta-
tus, educational status and occupational status of the 
participants (p  >  0.05). This was in line with finding by 
of other researchers from Zambia [33] and Gonder [25].
However, hospitalization, tooth extraction and blood 
transfusion showed statistically significant association with 
HCV infection (p  <  0.05). This was supported by other 
reports from Ethiopia [12, 18]. On the other hand, these var-
iables were not significantly associated with HCV infection 
in the study conducted in Hawassa [19] and Addis Ababa 
[17]. None of the HCV antibody positive study participants 
had history of intravenous drug use. This might be due to 
the fact that it is uncommon practice in the study area.
Limitation
Rapid test kit was used to detect anti HCV prevalence, 
hence may not detect early HCV infections like what the 
ELISA and PRC tests do.
Conclusion
The overall sero prevalence of HCV in this study was 
high; hospitalization, tooth extraction and blood trans-
fusion were significantly associated with HCV infec-
tion. The prevalence was three times higher among 
HIV positive than their counter parts. Therefore, rou-
tine screening programme of HCV infection in HIV-
infected patients is should be in place for the better 
management of the patients and prevent them from 
further complications. Implementation of more effec-
tive public health education and counseling on the risk 
factors should be given to reduce the burden of HIV/
HCV co-infection.
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 Yes 3 (10.0) 27 (90.0) 30 (9.9) 2.018 0.128
 No 10 (3.7) 262 (96.3) 272 (90.1)
Unsafe injection
 Yes 2 (12.5) 14 (87.5) 16 (5.3) 1.908 0.146
 No 11 (3.8) 275 (96.2) 286 (94.7)
Visiting traditional healers
 Yes 2 (7.7) 24 (92.3) 26 (8.6) 0.662 0.310
 No 11 (4.0) 265 (96.0) 276 (91.4)
Hospitalization
 Yes 10 (12.8) 68 (87.2) 78 (25.8) 15.635 0.001
 No 3 (1.3) 221 (98.7) 224 (74.2)
Tooth extraction
 Yes 4 (15.4) 22 (84.6) 26 (8.6) 5.569 0.018
 No 9 (3.3) 267 (96.7) 276 (91.4)
Surgical operation
 Yes 2 (8.7) 21 (91.3) 23 (7.6) 0.931 0.259
 No 11 (3.9) 268 (96.1) 279 (92.4)
Blood transfusion
 Yes 2 (25.0) 6 (75.0) 8 (2.6) 4.349 0.041
 No 11 (3.7) 283 (96.3) 294 (97.4)
Occupational exposure to blood
 Yes 1 (8.3) 11 (91.7) 12 (4.0) 0.395 0.416
 No 12 (4.1) 278 (95.9) 290 (96.0)
Multiple sexual partners
 Yes 4 (6.6) 57 (93.4) 61 (20.2) 0.850 0.305
 No 9 (3.7) 232 (96.3) 241 (79.8)
STI
 Yes 3 (9.4) 29 (90.6) 32 (10.6) 1.761 0.148
 No 10 (3.7) 260 (96.3) 270 (89.4)
Abortion
 Yes 2 (6.9) 27 (93.1) 29 (9.6) 0.815 0.301
 No 4 (3.1) 126 (96.9) 130 (90.4)
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